Effects of Positive Psychology Interventions on Risk Biomarkers in Coronary Patients: A Randomized, Wait-List Controlled Pilot Trial

• Published in: Psychosomatics (Washington, D.C.) Vol. 57; no. 4; pp. 359 - 368
• Main Authors: Nikrahan, Gholam Reza, Ph.D, Laferton, Johannes A.C., Ph.D, Asgari, Karim, Ph.D, Kalantari, Mehrdad, Ph.D, Abedi, Mohammad Reza, Ph.D, Etesampour, Ali, M.D, Rezaei, Abbas, Ph.D, Suarez, Laura, M.D, Huffman, Jeff C., M.D
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.07.2016
• Subjects: Aged; Biomarkers - metabolism; C-Reactive Protein - metabolism; Coronary Artery Bypass; coronary artery disease; Coronary Artery Disease - metabolism; Coronary Artery Disease - psychology; Coronary Artery Disease - surgery; Depression - psychology; Female; HPA-axis functioning; Humans; Hydrocortisone - metabolism; Hypothalamo-Hypophyseal System; inflammation; Interleukin-1 - metabolism; Interleukin-6 - metabolism; Internal Medicine; intervention; Male; Middle Aged; Percutaneous Coronary Intervention; Pilot Projects; Pituitary-Adrenal System; positive psychology; Psychiatry; randomized controlled trial; Risk; Saliva - chemistry; Waiting Lists; coronary artery disease; positive psychology; HPA-axis functioning; intervention; inflammation; randomized controlled trial
• ISSN: 0033-3182; 1545-7206
• DOI: 10.1016/j.psym.2016.02.007

Background Among cardiac patients, positive psychologic factors are consistently linked with superior clinical outcomes and improvement in key markers of inflammation and hypothalamic-pituitary-adrenal axis functioning. Further, positive psychology interventions (PPI) have effectively increased psychologic well-being in a wide variety of populations. However, there has been minimal study of PPIs in cardiac patients, and no prior study has evaluated their effect on key prognostic biomarkers of cardiac outcome. Accordingly, we investigated the effect of 3 distinct PPIs on risk biomarkers in cardiac patients. Methods In an exploratory trial, 69 patients with recent coronary artery bypass graft surgery or percutaneous intervention were randomized to (1) one of three 6-week in-person PPIs (based on the work of Seligman, Lyubomirsky, or Fordyce) or (2) a wait-list control group. Risk biomarkers were assessed at baseline, postintervention (7 weeks), and at 15-week follow-up. Between-group differences in change from baseline biomarker levels were examined via random effects models. Results Compared with the control group, participants randomized to the Seligman ( B = −2.06; p = 0.02) and Fordyce PPI ( B = −1.54; p = 0.04) had significantly lower high-sensitivity C-reactive protein levels at 7 weeks. Further, the Lyubomirsky PPI ( B = −245.86; p = 0.04) was associated with a significantly lower cortisol awakening response at 7 weeks when compared with control participants. There were no other significant between-group differences. Conclusion Despite being an exploratory pilot study with multiple between-group comparisons, this initial trial offers the first suggestion that PPIs might be effective in reducing risk biomarkers in high-risk cardiac patients.